Fulcrum Therapeutics

Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients. The company develops a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability. It is focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases.